All News
New indications for JAK inhibitors
There are several new positive RCTs for JAK inhibitors. Here is a summary of trials and new indications for JAKi in GCA, pediatrics, GI, dermatology and more.
Read Article
Is Rheumatoid Arthritis Preventable?
Many conventional synthetic, biological, biosimilar, and targeted synthetic disease-modifying anti-rheumatic drugs are currently commercially available for the effective treatment of rheumatoid arthritis. However, the "Holy Grail" remains the prevention of its development. During a clinical symposium at EULAR 2024 in Vienna, updates were presented on four prospective intervention trials conducted in patients experiencing joint pain without visible joint swelling.
Read Article
A Puzzling Era in Global Drug Development?
Dr. Eric Ruderman offers his observation regarding a puzzling global drug development observation, at Eular 2024 in Vienna, Austria.
https://t.co/A4KQovIt3u https://t.co/TQHJnSkIod
Dr. John Cush RheumNow ( View Tweet)
Be-GIANT cohort, 44.3% pts met definition of early axSpA (<2 yr Sxs). early axSpA had younger age and lower frequency of radiographic sacroiliitis. MDs think early disease to be more severe with higher physician global than late axSpA @synovialjoints #EULAR2024 Abstract POS0443 https://t.co/97J9tg0XZg
Dr. John Cush RheumNow ( View Tweet)
FDA has approved sarilumab (Kevzara) for the treatment of active polyarticular juvenile idiopathic arthritis (pJIA) in patients weighing 63 kg (138.891 lbs) or greater. https://t.co/b9NgyJVF2J https://t.co/cKoVxeBYIw
Dr. John Cush RheumNow ( View Tweet)
Abbvie announced upadacitinib (Rinvoq) is approved for use in polyarticular JIA and Psoriatic Arthritis (in children 2 years of age and older who have had an inadequate response or intolerance to 1 or more tumor necrosis factor (TNF) blockers) https://t.co/I4Wu49xGxy https://t.co/nTwgfRG1qG
Dr. John Cush RheumNow ( View Tweet)
Work ability impaired in majority of axSpA measured by the WAI score. 996 pts w a mean WAI score of 31.7. Overall, 28%/43%pts were in poor/moderate work ability, older, more often obese, w/ lower education, & phys work @synovialjoints #EULAR2024 Abstract POS0437
@RheumNow https://t.co/rQ4BunCn6T
Dr. John Cush RheumNow ( View Tweet)
Systemic Score in AOSD to Predict Life-threatening Complications
Dr. Bella Mehta discusses abstract OP0001 presented at Eular 2024 in Vienna, Austria.
https://t.co/Vw9prpAqKd https://t.co/RhGhDuJ8b2
Dr. John Cush RheumNow ( View Tweet)
The Crossroads of Autoinflammation and Autoimmunity
Dr. Andrea Fava shares his perspectives on autoinflammation and autoimmunity, a topic covered by many sessions at Eular 2024 in Vienna, Austria.
https://t.co/PXdHTWqVsX https://t.co/VZbZBk3a9f
Dr. John Cush RheumNow ( View Tweet)
The path to new technologies in rheumatology must be beset with caution
https://t.co/rostCE3UFT https://t.co/bn352RmrN8
Dr. John Cush RheumNow ( View Tweet)
Personalized Exercise may have Key Benefits in AxSpa
At EULAR, researchers demonstrated that personalized, supervised exercise therapy significantly improves physical function and quality of life for people with AxSpA and severe functional limitations.
https://t.co/TUP6hoLgJ4 https://t.co/t1gNQBdFzh
Dr. John Cush RheumNow ( View Tweet)
Enhance your clinical practice with insights from the EULAR 2024 Poster Hall Presentations, now on https://t.co/V10S4oVFsv. This year's conference showcases pivotal research in rheumatology. Visit https://t.co/58cJsSROsE to stay at the forefront of medical innovation. https://t.co/jbbufRQ6MW
Dr. John Cush RheumNow ( View Tweet)
Rituximab vs. Tocilizimab for Scleroderma: Which is Better?
Dr. Janet Pope discusses abstract OP0295 presented at Eular 2024 in Vienna, Austria.
https://t.co/70YF2wxwj5 https://t.co/8BHCafFs3u
Dr. John Cush RheumNow ( View Tweet)
Has JAK POT Hit the Spot About Infection Risk?
Dr. Yuz Yusof discusses abstract OP0092 presented at Eular 2024 in Vienna, Austria.
https://t.co/vN2VZYGqbE https://t.co/MQ3QCJU4SW
Dr. John Cush RheumNow ( View Tweet)
DMARDs and Herpes Zoster Vaccination: To Stop or Not To Stop
Dr. Jonathan Kay discusses abstracts POS0620 and OP0020 presented at Eular 2024 in Vienna, Austria.
https://t.co/gKJRygBeq0 https://t.co/2NTNYJLPNZ
Dr. John Cush RheumNow ( View Tweet)
Damage in Childhood Lupus
Childhood lupus (cSLE) is a rare multisystem disorder with significant associated morbidity, but evidence-based guidelines are sparse, and as such management is often based on clinical expertise.
https://t.co/wCygK0LGvd https://t.co/tm8LTI28mh
Dr. John Cush RheumNow ( View Tweet)
RA: update for women of child bearing potential (and men!)
Fertility in the context of RMDs is a daily concern for a lot of rheumatologists and patients.
https://t.co/RrkR2V3CI3 https://t.co/CRXUKxUqF2
Dr. John Cush RheumNow ( View Tweet)
Difficult-to-treat Rheumatoid Arthritis: Validation of the EULAR Definition
Dr. Mrinalini Dey discusses abstract OP0156 presented at Eular 2024 in Vienna, Austria.
https://t.co/oc3Aj60KsM https://t.co/40FMjbKEHF
Dr. John Cush RheumNow ( View Tweet)
EULAR 2024 Daily Recap: Days 1 & 2
Dr. Jack Cush moderates EULAR 2024 RECAP for days 1 & 2 with Drs. Mrinalini Day and Yuz Yusof in Vienna, Austria.
https://t.co/gRMVUXhTxw https://t.co/YV8vjVUCJn
Dr. John Cush RheumNow ( View Tweet)
Rituximab to Treat Systemic Features of Sjogren's
Dr. Yuz Yusof discusses abstract OP0076 presented at Eular 2024 in Vienna, Austria.
https://t.co/9oJNz12cCI https://t.co/bZxpbf3PT9
Dr. John Cush RheumNow ( View Tweet)